The choice of drug therapy in pregnant patients suffering from vaginal infections is limited 17 by the safety profile of the drug. Assuring the efficient topical therapy to avoid systemic 18 absorption is considered the best therapy option. Chitosan-coated liposomes have been 19 developed and optimized to assure localized therapy of clotrimazole. Chitosan was selected 20 as mucoadhesive polymer both to prolong system's retention at the vaginal site and act on 21 biofilms responsible for high recurrence of infections. Sonicated liposomes were coated 22 with chitosan in three different concentrations, namely 0.1, 0.3 and 0.6 % (w/v). 
Introduction 37
Although the occurrence of vaginal infections in pregnancy is common, the choice of drug 38 therapy is rather limited (das Neves et al., 2008) . In particular, topical antifungal therapy is 39 preferred due to the systemic toxicity of antifungal drugs (Chang et al., 2002) . In pregnant 40 patients, the two main therapy goals can be summarized as i) assuring the high local drug 41 concentration with concomitant avoidance of systemic absorption and ii) prevention of 42 infection recurrence (Vanić and Škalko-Basnet, 2013) . We propose that coating of 43 liposomal surfaces with chitosan can assure both of the goals. When vagina is the site of 44 drug administration, it is also important that both the drug and corresponding delivery 45 system are safe and non-irritating to the delicate vaginal mucosa (Woodrow et al., 2009) . 46 The selection of mucoadhesive polymer will be therefore based on its biodegradability, 47 9 drop-wise to an equal volume of liposomes free from unentrapped clotrimazole, under 161 controlled magnetic stirring at room temperature for 1 hour, followed by incubation in the 162 refrigerator overnight. The rate of stirring was kept constant for all preparations (Karn et 163 al., 2011) . 164 165
In vitro release study 166
Drug release was followed by the method described earlier . The Franz 167 cell manual diffusion system (Perme Gear Ink, Diffusion cells and Systems, Hellertown, 168 USA) was properly cleaned with methanol, demineralized water and distilled water, 169 respectively. The heating circulator (Julabo Laboratechnik, F12-ED, Seelback, Germany) 170 was set to 37°C. The acceptor chamber (12 mL) was filled up with acetate buffer (pH 4.6; 171 77.1 g of CH 3 COONH 4 , 70 mL of glacial acetic acid and distilled water up to 1000 mL). 172
Cellophane membrane (Max Bringmann KG, Wendelstein, Germany) was pre-soaked in 173 the same buffer. Liposomal samples (both chitosan-coated and non-coated and sonicated 174 for 2x2 min) or controls (clotrimazole in propylene glycol) were added in the donor 175 chamber and the system was properly sealed. The drug content in all tested samples was 176 determined (HPLC) prior to the study and the volumes of formulations in donor chambers 177 normalized to assure the same drug amount. The samples (500 µl) were collected after 1, 2, 178 3, 4, 8 and 24 hours. The samples were replaced by an equal volume of buffer upon 179 removal of sample from the acceptor chamber. The drug content was determined by the 180 HPLC method. The experiments were performed in triplicates. 181 10 182
Preparation of vaginal tissue 183
The sheep vaginal tissue (from pregnant animals) was obtained from the Laboratory 184
Animal Centre, University of Oulu, Finland. The vaginal tissue was carefully removed 185 from the underlying tissue and cleaned with the physiological solution (pH 7.4). Adequate 186 sized pieces were moisten by 0.9 % (w/w) NaCl and packed in clinging film, and frozen (-187 20°C). They were left to defrost at room temperature for at least 2 hours prior to 188 experiments. The thickness of the tissue was determined to be ranging from 900 to 1140 189 microns. It was earlier confirmed that no significant differences were observed in using 190 fresh or snap-frozen tissue samples (Sassi et al., 2004 
Results and Discussion

222
In order to achieve optimal therapeutic outcome, the delivery system is expected to provide 223 a sufficient amount of the active ingredient (in our case clotrimazole) at the desired site of 224 action (vaginal mucosal tissue) for a sufficiently long period of time to enable drug to 225 perform its therapeutic action. Therefore, in the first step in optimization of chitosan-coated 226 liposomes for topical vaginal delivery, we were focusing on the relationship between 227 encapsulation yields vs particle size. Smaller particles are expected to provide larger 228 surface area, however those particles carry less clotrimazole load, whereas larger particles 229 will incorporate more of the drug, but will provide smaller contact surface for possible 230 mucoadhesion. 231 The particle size shown in Table 1 indicates that the liposomes sonicated for 2x2 minutes 255 were in the desired size range. Liposomal dispersions exhibited two distinguished peaks in 256 distributions, indicating bimodal distribution and rather high polydispersity (Table 1) . With 257 the increase in sonication time, the polydispersity index values decreased, as expected 258 (Table 1) . 259
We tried to minimize the exposure of liposomes to the sonication force, as it is known that 260 extensive sonication can lead to the release of originally incorporated drug and lipid 261 degradation (di Cagno et al., 2011). 262
Due to highly lipophilic nature of clotrimazole (log P of 3.5), clotrimazole was dissolved in 263 the organic solvent together with lipid during the preparation of liposomes and was 264 14 expected to incorporate itself within lipid bilayers of liposomes. We observed similar 265 entrapment efficiencies for liposomes sonicated for 1 and 2 minutes, and the loss of 266 originally entrapped clotrimazole was remarkable only after sonication for 2x2 minutes, 267 resulting in smaller liposomes (Table 1) . In comparison to literature data, our entrapment 268 very limited solubility in water. In the case of the control (propylene glycol), an osmotic 356 effect was observed drawing water from the acceptor medium into the sample in donor 357 chamber. As a consequence, clotrimazole started to precipitate (in donor chamber) when a 358 critical amount of drug dissolved in propylene glycol is mixed with water. Therefore, we 359 assume that it would be necessary to add some sort of the solubilizing agent into the 360 acceptor medium (acceptor chamber) to secure sink conditions. The limitation of Franz 361 diffusion system is the limited volume which can be used in the acceptor chamber, causing 362 the problems for the poorly soluble drugs. However, we could detect the differences 363 between control (free drug) and the drug released from liposomes. Although we have 364 expected the slowest release from chitosan-coated liposomes, interestingly, the slowest 365 release of the drug was perceived from non-coated Tables and Figures   656   657   Tables:  658   Table 1 : Liposomal characteristics (n=3) 659 
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